<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112439211</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112439211</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rapid Enrichment of Cell Phospholipids in Long-Chain Polyunsaturated ω-3 Fatty Acids After a Bolus Intravenous Injection of a Medium-Chain Triacylglycerol</article-title>
<subtitle>Fish Oil Emulsion in Humans</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Carpentier</surname><given-names>Yvon A.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607112439211">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Portois</surname><given-names>Laurence</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607112439211">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Malaisse</surname><given-names>Willy J.</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0148607112439211">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607112439211"><label>1</label>Laboratories of Experimental Surgery, Université Libre de Bruxelles, Brussels, Belgium</aff>
<aff id="aff2-0148607112439211"><label>2</label>Laboratories of Experimental Hormonology, Université Libre de Bruxelles, Brussels, Belgium</aff>
<author-notes>
<corresp id="corresp1-0148607112439211">Willy J. Malaisse, Laboratory of Experimental Hormonology, Université Libre de Bruxelles, 808 Route de Lennik, B-1070 Brussels, Belgium; e-mail: <email>malaisse@ulb.ac.be</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>36</volume>
<issue>6</issue>
<fpage>671</fpage>
<lpage>676</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>11</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>9</day>
<month>1</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>The present review aims at highlighting the use of a recently developed medium-chain triacylglycerol:fish oil (MCT:FO) emulsion for the rapid and sustained enrichment of long-chain polyunsaturated ω-3 fatty acids in cell phospholipids. Preclinical in vitro, in vivo, and ex vivo experiments are briefly considered with emphasis on the changes in the fatty acid pattern of cell phospholipids in several organs, the partial correction of liver steatosis, and the cardiovascular modification of cationic and functional variables observed in ω-3-depleted rats examined 60–120 minutes after a bolus intravenous (IV) injection (1.0 mL) of the MCT:FO emulsion. The clinical findings collected in healthy male volunteers before or after the bolus IV injection (50.0 mL) of either the MCT:FO emulsion or a control medium-chain triacylglycerol:long-chain triacylglycerol emulsion are also reviewed, with emphasis on the rapid (within 60 minutes) and sustained (up to 2–3 days) enrichment of platelet and white blood cell phospholipids in long-chain polyunsaturated ω-3 fatty acids and hemostatic safety of the present procedure proposed as a tool for the rapid prevention or correction of metabolic and functional disturbances in humans with a relative deficiency in such ω-3 fatty acids.</p>
</abstract>
<kwd-group>
<kwd>long-chain polyunsaturated ω-3 fatty acids</kwd>
<kwd>medium-chain triacylglycerol:fish oil emulsion</kwd>
<kwd>cell phospholipids</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Patterns in dietary lipid intake in Western populations are characterized by increased intake of long-chain polyunsaturated ω6 fatty acids and reduced uptake of long-chain polyunsaturated ω-3 fatty acids (ω-3PUFA).<sup><xref ref-type="bibr" rid="bibr1-0148607112439211">1</xref></sup> The efficacy of dietary supplementation in ω-3PUFA requires at least a few days, if not weeks, because their incorporation in the cell membrane is relatively slow after oral ingestion of fish oil.<sup><xref ref-type="bibr" rid="bibr2-0148607112439211">2</xref><xref ref-type="bibr" rid="bibr3-0148607112439211"/>-<xref ref-type="bibr" rid="bibr4-0148607112439211">4</xref></sup> The time course for the enrichment of cell phospholipids in ω-3PUFA and for the correction of other metabolic variables was recently reexamined in ω-3-depleted rats first exposed to a sunflower oil diet and then switched to a soya, flaxseed, or fish oil diet.<sup><xref ref-type="bibr" rid="bibr5-0148607112439211">5</xref><xref ref-type="bibr" rid="bibr6-0148607112439211"/><xref ref-type="bibr" rid="bibr7-0148607112439211"/><xref ref-type="bibr" rid="bibr8-0148607112439211"/><xref ref-type="bibr" rid="bibr9-0148607112439211"/><xref ref-type="bibr" rid="bibr10-0148607112439211"/><xref ref-type="bibr" rid="bibr11-0148607112439211"/><xref ref-type="bibr" rid="bibr12-0148607112439211"/><xref ref-type="bibr" rid="bibr13-0148607112439211"/><xref ref-type="bibr" rid="bibr14-0148607112439211"/><xref ref-type="bibr" rid="bibr15-0148607112439211"/><xref ref-type="bibr" rid="bibr16-0148607112439211"/><xref ref-type="bibr" rid="bibr17-0148607112439211"/><xref ref-type="bibr" rid="bibr18-0148607112439211"/>-<xref ref-type="bibr" rid="bibr19-0148607112439211">19</xref></sup></p>
<p>Lipid emulsions rich in ω-3 fatty acids are currently used for parenteral nutrition (PN), and some of them are commercially available.<sup><xref ref-type="bibr" rid="bibr20-0148607112439211">20</xref>,<xref ref-type="bibr" rid="bibr21-0148607112439211">21</xref></sup> To cite only two examples, the use of such emulsions was considered in acute respiratory distress syndrome<sup><xref ref-type="bibr" rid="bibr22-0148607112439211">22</xref></sup> and was found efficient for liver salvage in PN-induced intrahepatic cholestasis.<sup><xref ref-type="bibr" rid="bibr23-0148607112439211">23</xref></sup></p>
<p>The present review aims at drawing attention to the use of a recently developed medium-chain triacylglycerol:fish oil (MCT:FO) emulsion found to provoke, after bolus intravenous (IV) injection, a rapid and sustained increase in the ω-3PUFA content of cell phospholipids in human participants.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref></sup> The experimental work that led to the development of this novel approach to rapidly supply ω-3PUFA to targeted organs, which may offer interesting perspectives in the management of acute illnesses, was first reviewed in 2006.<sup><xref ref-type="bibr" rid="bibr25-0148607112439211">25</xref></sup> The MCT:FO emulsion is a 20-g/100-mL triacylglycerol emulsion containing 80% MCT and 20% FO (wt:wt). The C20:5ω-3, C22:5ω-3, and C22:6ω-3 present in this emulsion are provided by its FO moiety.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref></sup> It also contained 1.2 g/100 mL egg-derived phospholipid emulsifier.</p>
<sec id="section1-0148607112439211">
<title>Preclinical Findings</title>
<p>Preclinical studies dealt with in vitro experiments on the lipoprotein lipase-catalyzed hydrolysis of lipids in the MCT:FO and other emulsions. In addition, attention was paid to the incorporation of ω-3PUFA from the MCT:FO and other lipid emulsions into the phospholipids of cultured endothelial cells. Both in vivo and ex vivo investigations were also conducted mainly, but not exclusively, in second-generation ω-3-depleted rats.</p>
<p>In the in vitro work concerning the effects of bovine milk lipoprotein lipase on the lipid composition of several emulsions, emphasis was placed on differences in the fate of distinct fatty acids initially present in triglycerides, diglycerides, and phospholipids; on the generation of unesterified fatty acids; and on the time course for these various events.<sup><xref ref-type="bibr" rid="bibr26-0148607112439211">26</xref>,<xref ref-type="bibr" rid="bibr27-0148607112439211">27</xref></sup> In the experiments conducted on cultured endothelial cells, attention was drawn on a comparison between the MCT:FO and other emulsions, as well as serum albumin–bound ω-3PUFA, in terms of the time course, reversibility, and concentration dependency for the incorporation of ω-3PUFA in the phospholipids and triglycerides of these endothelial cells.<sup><xref ref-type="bibr" rid="bibr28-0148607112439211">28</xref></sup></p>
<p>The in vivo work concerned the enrichment of cell phospholipids and triglycerides in ω-3PUFA after a bolus IV injection of the MCT:FO or other emulsions in second-generation ω-3-depleted rats, as well as streptozotocin (type 1) and Goto-Kakizaki (type 2) diabetic rats. In these experiments, the organs under consideration included liver,<sup><xref ref-type="bibr" rid="bibr29-0148607112439211">29</xref><xref ref-type="bibr" rid="bibr30-0148607112439211"/><xref ref-type="bibr" rid="bibr31-0148607112439211"/><xref ref-type="bibr" rid="bibr32-0148607112439211"/><xref ref-type="bibr" rid="bibr33-0148607112439211"/><xref ref-type="bibr" rid="bibr34-0148607112439211"/>-<xref ref-type="bibr" rid="bibr35-0148607112439211">35</xref></sup> parametrial and epiploic fat,<sup><xref ref-type="bibr" rid="bibr32-0148607112439211">32</xref>,<xref ref-type="bibr" rid="bibr36-0148607112439211">36</xref></sup> soleus muscle,<sup><xref ref-type="bibr" rid="bibr37-0148607112439211">37</xref><xref ref-type="bibr" rid="bibr38-0148607112439211"/>-<xref ref-type="bibr" rid="bibr39-0148607112439211">39</xref></sup> brain,<sup><xref ref-type="bibr" rid="bibr40-0148607112439211">40</xref></sup> heart muscle and cardiomyocytes,<sup><xref ref-type="bibr" rid="bibr41-0148607112439211">41</xref>,<xref ref-type="bibr" rid="bibr42-0148607112439211">42</xref></sup> and submandibular gland.<sup><xref ref-type="bibr" rid="bibr43-0148607112439211">43</xref></sup> The concentration and fatty acid pattern of plasma phospholipids, triglycerides, diglycerides, and nonesterified fatty acids were also measured 60–120 minutes after injection of the MCT:FO emulsion or a control medium-chain triglyceride:olive oil emulsion,<sup><xref ref-type="bibr" rid="bibr29-0148607112439211">29</xref>,<xref ref-type="bibr" rid="bibr31-0148607112439211">31</xref>,<xref ref-type="bibr" rid="bibr32-0148607112439211">32</xref>,<xref ref-type="bibr" rid="bibr44-0148607112439211">44</xref><xref ref-type="bibr" rid="bibr45-0148607112439211"/>-<xref ref-type="bibr" rid="bibr46-0148607112439211">46</xref></sup> and the results of such measurements were compared with those collected in the liver lipids of the same animals.<sup><xref ref-type="bibr" rid="bibr47-0148607112439211">47</xref><xref ref-type="bibr" rid="bibr48-0148607112439211"/>-<xref ref-type="bibr" rid="bibr49-0148607112439211">49</xref></sup> To cite two examples, such investigations revealed both a preferential enrichment of liver phospholipids in C22:6ω-3 relative to C20:5ω-3<sup><xref ref-type="bibr" rid="bibr35-0148607112439211">35</xref></sup> and a partial correction of liver steatosis<sup><xref ref-type="bibr" rid="bibr33-0148607112439211">33</xref></sup> in second-generation ω-3-depleted rats injected with the MCT:FO emulsion 60 minutes before sacrifice.</p>
<p>Last, the ex vivo experiments conducted in tissue samples usually obtained from second-generation ω-3-depleted rats injected prior to sacrifice with the MCT:FO emulsion or a suitable control emulsion aimed at investigating (1) the metabolism of D-[U-<sup><xref ref-type="bibr" rid="bibr14-0148607112439211">14</xref></sup>C]glucose (ie, its conversion to glycogen, acidic metabolites, and amino acids in hemidiaphragms, stretched soleus, and plantaris muscle pieces incubated in the absence or presence of insulin)<sup><xref ref-type="bibr" rid="bibr37-0148607112439211">37</xref></sup>; (2) the basal and insulin-stimulated net uptake of D-[U-<sup><xref ref-type="bibr" rid="bibr14-0148607112439211">14</xref></sup>C]glucose and [1,2-<sup><xref ref-type="bibr" rid="bibr14-0148607112439211">14</xref></sup>C]acetate, as well as basal and theophylline-stimulated lipolysis, in isolated adipocytes prepared from parametrial fat<sup><xref ref-type="bibr" rid="bibr32-0148607112439211">32</xref></sup>; (3) the handling of <sup>86</sup>Rb<sup>+</sup> and <sup>45</sup>Ca<sup>2+</sup>, metabolism of D-glucose, and release of insulin by isolated pancreatic islets exposed to nutrient and nonnutrient secretagogues<sup><xref ref-type="bibr" rid="bibr29-0148607112439211">29</xref>,<xref ref-type="bibr" rid="bibr30-0148607112439211">30</xref>,<xref ref-type="bibr" rid="bibr50-0148607112439211">50</xref>,<xref ref-type="bibr" rid="bibr51-0148607112439211">51</xref></sup>; and (4) the cationic fluxes in aortic rings, aortic endothelium function as assessed by the vasomotor response to acetylcholine in isolated aortic rings contracted with phenylephrine, postischemic recovery of perfused hearts, and cationic fluxes and Na<sup>+</sup>,K<sup>+</sup>-ATPase activity in ventricular cardiomyocytes.<sup><xref ref-type="bibr" rid="bibr42-0148607112439211">42</xref>,<xref ref-type="bibr" rid="bibr52-0148607112439211">52</xref><xref ref-type="bibr" rid="bibr53-0148607112439211"/>-<xref ref-type="bibr" rid="bibr54-0148607112439211">54</xref></sup></p>
<p>The latter cardiovascular investigations in second-generation ω-3-depleted rats aimed mainly at identifying possible changes in relevant variables recorded after the bolus IV injection of the MCT:FO emulsion. Hence, it was assessed whether this novel approach for the enrichment of membrane phospholipids in ω-3PUFA may conceivably represent, in contrast with the long-term exposure to a diet enriched in these ω-3 fatty acids, a rapid and efficient procedure for the prevention of undesirable functional events, such as cardiac arrhythmia following anesthesia and/or surgery.</p>
<p>It was initially observed that, within 2 hours after the bolus IV injection of the MCT:FO emulsion in second-generation ω-3-depleted rats, cationic fluxes in aortic rings indeed differed from those recorded after injection of a control MCT:OO emulsion (medium-chain triglyceride:olive oil emulsion). That is, the injection of the MCT:FO, as distinct from the MCT:OO, emulsion restored responsiveness to a high extracellular K<sup>+</sup> concentration (60 mM) in terms of stimulation of <sup>45</sup>Ca<sup>2+</sup> net uptake above the basal value found at 5 mM K<sup>+</sup>. Likewise, the net uptake of <sup>86</sup>Rb<sup>+</sup> by aortic rings incubated for 10–60 minutes in the presence or absence of ouabain (50 µM) only represented in the MCT:FO-injected rats 63.1% ± 3.8% (<italic>P</italic> &lt; .001) of the mean corresponding values found under the same experimental conditions in rings from animals injected with the MCT:OO emulsion.<sup><xref ref-type="bibr" rid="bibr52-0148607112439211">52</xref></sup></p>
<p>Even 20 hours after injection of the MCT:FO emulsion (as compared with a medium-chain triacylglycerol:long-chain triacylglycerol [MCT:LCT] emulsion) to normal or streptozotocin-induced diabetic rats, aortic rings were protected against the deleterious effects of oxidized low-density lipoprotein (LDL) on the vasomotor response to acetylcholine in phenylephrine precontracted rings. In the diabetic rats, a beneficial effect of the MCT:FO emulsion was even observed prior to the exposure to the aortic rings to oxidized LDL.<sup><xref ref-type="bibr" rid="bibr53-0148607112439211">53</xref></sup></p>
<p>A third set of investigations aimed at exploring the effect of a single IV injection of the MCT:FO emulsion (1.0 mL) on the recovery of cardiac function after ex vivo ischemia in control and ω-3-depleted rats. Control experiments included the IV injection of either saline (1.0 mL) or the MCT:OO emulsion (1.0 mL). Sixty minutes thereafter, the heart was removed and, in a progressive manner, first perfused for 20 minutes under normoxic conditions, then subjected to 20-minute zero-flow normothermic ischemia, and eventually submitted for 40 minutes to an aerobic postischemic reperfusion. The ω-3-depleted rats showed decreased basal cardiac function and impaired recovery following ischemia. However, the bolus IV injection of the MCT:FO emulsion opposed the deleterious effects of long-term ω-3PUFA deficiency and, in this respect, was superior to the MCT:OO emulsion, at least over the first 20 minutes of reperfusion.<sup><xref ref-type="bibr" rid="bibr54-0148607112439211">54</xref></sup></p>
<p>Finally, ventricular cardiomyocytes from second-generation ω-3-depleted rats, which presented the same changes in the phospholipid fatty acid pattern as that previously documented in the cardiac muscle and endothelium of such rats,<sup><xref ref-type="bibr" rid="bibr41-0148607112439211">41</xref>,<xref ref-type="bibr" rid="bibr55-0148607112439211">55</xref></sup> were found to display ex vivo altered <sup>86</sup>Rb and <sup>45</sup>Ca fluxes. These were corrected, at least in part, by the prior injection 60 minutes before sacrifice of the MCT:FO emulsion.<sup><xref ref-type="bibr" rid="bibr42-0148607112439211">42</xref></sup> <xref ref-type="table" rid="table1-0148607112439211">Table 1</xref> documents the estimation of K and Ca cell content at isotopic equilibrium in control rats, not-injected ω-3-depleted rats, and ω-3-depleted rats injected with either the MCT:FO or control MCT:OO emulsion.</p>
<table-wrap id="table1-0148607112439211" position="float">
<label>Table 1.</label>
<caption>
<p>Potassium and Calcium Cell Content at Isotopic Equilibrium of Ventricular Cardiomyocytes From Control Animals and ω-3-Depleted Rats Either Not Injected (ω-3D-NI) or Injected 60 Minutes Before Sacrifice With the MCT:OO (ω-3D-OO) or MCT:FO (ω-3D-FO) Emulsion</p>
</caption>
<graphic alternate-form-of="table1-0148607112439211" xlink:href="10.1177_0148607112439211-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Rats</th>
<th align="center">Control</th>
<th align="center">ω-3D-NI</th>
<th align="center">ω-3D-OO</th>
<th align="center">ω-3D-FO</th>
</tr>
</thead>
<tbody>
<tr>
<td>K cell content, fmol/cell</td>
<td>543 ± 7</td>
<td>198 ± 1</td>
<td>176 ± 5</td>
<td>269 ± 5</td>
</tr>
<tr>
<td>Ca cell content, fmol/cell</td>
<td>29.7 ± 2.2</td>
<td>43.0 ± 0.3</td>
<td>43.8 ± 0.95<sup><xref ref-type="table-fn" rid="table-fn2-0148607112439211">a</xref></sup></td>
<td>33.6 ± 4.8</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607112439211">
<p>MCT:FO, medium-chain triacylglycerol:fish oil.</p>
</fn>
<fn id="table-fn2-0148607112439211">
<label>a</label>
<p>Estimated from the comparison between the values recorded in cardiomyocytes prepared from ω-3D-NI and ω-3D-OO rats and incubated at 30 and 60 mM K<sup>+</sup>.<sup><xref ref-type="bibr" rid="bibr42-0148607112439211">42</xref></sup></p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section2-0148607112439211">
<title>Clinical Findings</title>
<p>Three reports were recently published concerning the results (baseline and postinjection) collected in 12 healthy male volunteers who received a bolus IV injection (50 mL) of the MCT:FO emulsion.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref>,<xref ref-type="bibr" rid="bibr56-0148607112439211">56</xref>,<xref ref-type="bibr" rid="bibr57-0148607112439211">57</xref></sup> A control emulsion (MCT:LCT) was a 20% (w/v) emulsion containing equal amounts of medium-chain lipids and soybean long-chain triglycerides, currently used for PN (Medialipid; B. Braun AG, Melsungen, Germany). It was injected 8 weeks before or 8 weeks after the injection of the MCT:FO emulsion. At hourly intervals during each test and at 8:00 AM on days 2, 3, and 8 thereafter, body temperature, heart rate, and blood pressure were monitored. Likewise, blood cell counts (including hemoglobin and hematocrit determinations), coagulation tests, and routine safety laboratory variables were measured before and again 1 and 8 hours and on days 2, 3, and 8 after the injection of a lipid emulsion.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref></sup> No adverse clinical effect was observed, and there were no change of biological variables that assessed tolerance and safety.</p>
<sec id="section3-0148607112439211">
<title>Plasma Triacylglycerol and Nonesterified Fatty Acid Concentration</title>
<p>The apparent distribution space of triacylglycerols was virtually identical after injection of the MCT:FO and MCT:LCT emulsion with an overall mean value of 3.92 ± 0.11 L. The clearance of plasma triacylglycerols was faster, however, with the MCT:FO emulsion (half-life: 24.5 ± 3.5 minutes) than with the MCT:LCT emulsion (half-life: 32.9 ± 3.0 minutes). The peak value (minute 30) and incremental area (over 45 minutes) for the plasma concentration of nonesterified fatty acids were significantly higher after injection of the MCT:FO, as compared with the MCT:LCT, emulsion.</p>
</sec>
<sec id="section4-0148607112439211">
<title>ω-3PUFA Content of Platelet and White Blood Cell Phospholipids</title>
<p>As indicated in <xref ref-type="table" rid="table2-0148607112439211">Table 2</xref>, no significant difference between the MCT:FO and MCT:LCT series was observed as far as the basal value for the C20:5ω-3, C22:5ω-3, and C22:6ω-3 relative weight content of either platelet or white blood cell (WBC) phospholipids is concerned. As judged by analysis of variance (ANOVA) for repeated measurements on treatment and time with interaction, the treatment response (MCT:FO vs MCT:LCT) for the C20:5ω-3 content was highly significant in both platelet and WBC phospholipids.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref></sup> According to the same statistical procedure, such was also the case for both the total ω-3PUFA content (C18:3ω-3, C20:5ω-3, C22:5ω-3, and C22:6ω-3) and the ratio between ω-3PUFA and ω6PUFA (C18:2ω6, C18:3ω6, and C20:4ω6) in platelet phospholipids.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref></sup> For the 3 variables under consideration, a plateau value was reached between 1 and 4 hours after injection of the MCT:FO emulsion, followed by a progressive decline on days 2 and 3 after such an injection. The magnitude of the changes in the C20:5ω-3 and C22:6ω-3 content of either platelet or WBC phospholipids is documented in <xref ref-type="table" rid="table2-0148607112439211">Table 2</xref>, which refers customarily to the mean increments recorded 1, 2, and 4 hours after injection of a given emulsion, as well as 1 and 2 days thereafter.<sup><xref ref-type="bibr" rid="bibr56-0148607112439211">56</xref></sup></p>
<table-wrap id="table2-0148607112439211" position="float">
<label>Table 2.</label>
<caption>
<p>Relative Weight Content (%) of ω-3PUFA in the MCT: FO and MCT:LCT Series</p>
</caption>
<graphic alternate-form-of="table2-0148607112439211" xlink:href="10.1177_0148607112439211-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Emulsion</th>
<th align="center">MCT:FO</th>
<th align="center">MCT:LCT</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Emulsion triacylglycerols</td>
</tr>
<tr>
<td> C20:5ω-3</td>
<td>4.9</td>
<td>0.0</td>
</tr>
<tr>
<td> C22:5ω-3</td>
<td>0.7</td>
<td>0.0</td>
</tr>
<tr>
<td> C22:6ω-3</td>
<td>5.0</td>
<td>0.0</td>
</tr>
<tr>
<td colspan="3">Basal value in platelet phospholipids</td>
</tr>
<tr>
<td> C20:5ω-3</td>
<td>0.41 ± 0.05</td>
<td>0.41 ± 0.06</td>
</tr>
<tr>
<td> C22:5ω-3</td>
<td>2.40 ± 0.10</td>
<td>2.41 ± 0.10</td>
</tr>
<tr>
<td> C22:6ω-3</td>
<td>2.76 ± 0.16</td>
<td>2.76 ± 0.16</td>
</tr>
<tr>
<td colspan="3">Basal value in WBC phospholipids</td>
</tr>
<tr>
<td> C20:5ω-3</td>
<td>0.59 ± 0.06</td>
<td>0.63 ± 0.09</td>
</tr>
<tr>
<td> C22:5ω-3</td>
<td>2.18 ± 0.13</td>
<td>2.04 ± 0.10</td>
</tr>
<tr>
<td> C22:6ω-3</td>
<td>3.63 ± 0.24</td>
<td>3.45 ± 0.22</td>
</tr>
<tr>
<td colspan="3">Increment in platelet phospholipids<sup><xref ref-type="table-fn" rid="table-fn4-0148607112439211">a</xref></sup></td>
</tr>
<tr>
<td> C20:5ω-3</td>
<td>+0.17 ± 0.01 (59)</td>
<td>−0.02 ± 0.01 (59)<sup><xref ref-type="table-fn" rid="table-fn6-0148607112439211">c</xref></sup></td>
</tr>
<tr>
<td> C22:6ω-3</td>
<td>+0.08 ± 0.01 (62)</td>
<td>0.00 ± 0.01 (63)<sup><xref ref-type="table-fn" rid="table-fn6-0148607112439211">c</xref></sup></td>
</tr>
<tr>
<td colspan="3">Increment in WBC phospholipids<sup><xref ref-type="table-fn" rid="table-fn5-0148607112439211">b</xref></sup></td>
</tr>
<tr>
<td> C20:5ω-3</td>
<td>+0.12 ± 0.02 (64)</td>
<td>−0.01 ± 0.01 (63)<sup><xref ref-type="table-fn" rid="table-fn6-0148607112439211">c</xref></sup></td>
</tr>
<tr>
<td> C22:6ω-3</td>
<td>+0.16 ± 0.06 (65)</td>
<td>+0.21 ± 0.04 (68)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0148607112439211">
<p>MCT:FO, medium-chain triacylglycerol:fish oil; MCT:LCT, medium-chain triacylglycerol:long-chain triacylglycerol; WBC, white blood cell.</p>
</fn>
<fn id="table-fn4-0148607112439211">
<label>a</label>
<p>Measurements made after injection of the MCT:FO and MCT:LCT emulsion, respectively, in the first 4.92 ± 0.25 and 4.92 ± 0.31 samples in the case of C20:5ω-3 and 5.17 ± 0.27 and 5.25 ± 0.25 samples in the case of C22:6ω-3 (n = 12 in all cases).</p>
</fn>
<fn id="table-fn5-0148607112439211">
<label>b</label>
<p>Measurements made after injection of the MCT:FO and MCT:LCT emulsion, respectively, in the first 5.33 ±0.22 and 5.25 ± 0.21 samples in the case of C20:5ω-3 and 5.42 ± 0.19 and 5.67 ± 0.14 samples in the case of C22:6ω-3 (n = 12 in all cases).</p>
</fn>
<fn id="table-fn6-0148607112439211">
<label>c</label>
<p>The difference between the mean values recorded in the MCT:FO and MCT:LCT series was highly significant (<italic>P</italic> &lt; .001).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The C18:3ω-3 relative weight content of phospholipids did not differ significantly in the MCT:FO and MCT:LCT series, either before or after administration of these emulsions and whether in platelets or WBC, with overall mean values in the MCT:FO and MCT:LCT series, respectively, of 3.76 ± 0.45 10<sup>–4</sup> (n = 84) and 3.79 ± 0.28 10<sup>–4</sup> (n = 80) in platelets and 6.95 ± 1.10 10<sup>–4</sup> (n = 84) and 6.76 ± 1.11 10<sup>–4</sup> (n = 83) in WBC. Likewise, no significant difference was found between the MCT:FO and MCT:LCT series in terms of the changes in the C22:5ω-3 relative weight content of platelet or WBC phospholipids above or below the paired basal value.<sup><xref ref-type="bibr" rid="bibr56-0148607112439211">56</xref></sup> However, in both platelet and WBC phospholipids, the C18:2ω6 and C20:4ω6 relative weight content underwent a more pronounced decrease after injection of the MCT:FO, as compared with the MCT:LCT, emulsion.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref>,<xref ref-type="bibr" rid="bibr56-0148607112439211">56</xref></sup></p>
</sec>
<sec id="section5-0148607112439211">
<title>LDL Sensitivity to Peroxidation</title>
<p>The α-tocopherol concentration was 4.0 mg/mL in MCT:FO and 0.2 mg/mL in MCT:LCT. As expected, the α-tocopherol content of LDL and high-density lipoprotein (HDL; expressed as µmol/mmol total cholesterol), as well as that of platelets and WBC (expressed as µmol/mmol phospholipids), increased much more after injection of the MCT:FO, as compared with the MCT:LCT, emulsion.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref></sup> This coincided with a decreased sensitivity to lipid peroxidation, as assessed by measuring both the lag time that preceded the appearance of conjugated dienes and the propagation slope of dienes upon LDL exposure to copper sulfate. In this respect, the difference between the MCT:FO and MCT:LCT series was always significant between 1 hour and 3 days after the injection of these emulsions.<sup><xref ref-type="bibr" rid="bibr24-0148607112439211">24</xref></sup></p>
</sec>
<sec id="section6-0148607112439211">
<title>Safety Variables</title>
<p>Special attention was dedicated to the hemostatic safety of the present protocol.<sup><xref ref-type="bibr" rid="bibr57-0148607112439211">57</xref></sup> For this purpose, platelet function was assessed by measuring the occlusion time of an aperture in a membrane coated either with collagen and the strong platelet activator ADP (ADP test) or with collagen and the weak platelet activator epinephrine (epinephrine test). For detection of platelet reactivity by flow cytometry, 3 combinations of markers were used. Each combination included a monoclonal antibody that targets all platelets, together with 2 other markers (ie, either PAC-1-fluorescein isothiocyanate and CD62p-phycoerythrin, fibrinogen-fluorescein isothiocyanate, and CD42b-phycoerythrin or irrelevant monoclonal antibodies from the same isotype fluorescein isothiocyanate and phycoerythrin as control). For each of the 3 marker combinations, the 4 following conditions were examined: unstimulated blood, blood stimulated with collagen, blood stimulated with ADP, and blood stimulated with thrombin receptor-activated peptide–6 (TRAP-6).</p>
<p>No adverse effect was found when comparing the results obtained after administration of either MCT:FO or MCT-LCT, whether in terms of the occlusion time in the ADP or epinephrine test or in terms of platelet reactivity, as assessed with each of the 3 marker combinations in response to collagen, ADP, or TRAP-6.<sup><xref ref-type="bibr" rid="bibr57-0148607112439211">57</xref></sup></p>
</sec>
</sec>
<sec id="section7-0148607112439211">
<title>Conclusion</title>
<p>Taken as a whole, the preclinical and clinical findings, considered in the present review, reinforce the proposal that the bolus IV injection of the MCT:FO emulsion represents a suitable procedure for the rapid enrichment of cell phospholipids in ω-3PUFA. Thus, it is possible to achieve rapid prevention or correction of metabolic and functional disturbances in humans presenting with a relative deficiency of such ω-3 fatty acids.</p>
</sec>
</body>
<back>
<ack><p>We are grateful to C. Demesmaeker for secretarial help.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112439211">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>N-E fatty acids and the metabolic syndrome</article-title>. <source>Am J Clin Nutr</source>. <year>2006</year>;<volume>83</volume>:<fpage>1499S</fpage>-<lpage>1504S</lpage>.</citation>
</ref>
<ref id="bibr2-0148607112439211">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Faber</surname><given-names>J</given-names></name>
<name><surname>Berkhout</surname><given-names>M</given-names></name>
<name><surname>Vos</surname><given-names>AP</given-names></name><etal/>
</person-group>. <article-title>Supplementation with a fish oil–enriched, high-protein medical food leads to rapid incorporation of EPA into white blood cells and modulates immune responses within one week in healthy men and women</article-title>. <source>J Nutr</source>. <year>2011</year>;<volume>141</volume>:<fpage>964</fpage>-<lpage>970</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112439211">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>MS</given-names></name>
<name><surname>Høy</surname><given-names>C-E</given-names></name>
<name><surname>Becker</surname><given-names>CC</given-names></name>
<name><surname>Redgrave</surname><given-names>TG</given-names></name>
</person-group>. <article-title>Intestinal absorption and lymphatic transport of eicosapentaenoic (EPA), docosahexaenoic (DHA), and decanoic acids: dependence on intramolecular triacylglycerol structure</article-title>. <source>Am J Clin Nutr</source>. <year>1995</year>;<volume>61</volume>:<fpage>56</fpage>-<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112439211">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>FL</given-names></name>
<name><surname>Rumsey</surname><given-names>SC</given-names></name>
<name><surname>Schlotzer</surname><given-names>E</given-names></name>
<name><surname>Hansen</surname><given-names>I</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Deckelbaum</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Triglyceride hydrolysis of soy oil vs fish oil emulsions</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1997</year>;<volume>21</volume>:<fpage>224</fpage>-<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112439211">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Larondelle</surname><given-names>Y</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. I. Intestinal phospholipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>3</fpage>-<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112439211">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. II. Relation between intestinal and hepatic phospholipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>10</fpage>-<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112439211">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. III. Liver phospholipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>14</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr8-0148607112439211">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. IV. Ratio between liver phospholipid fatty acids interconvertible in Δ9-desaturase-catalyzed reactions</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>23</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112439211">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. V. Red blood cell phospholipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>28</fpage>-<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr10-0148607112439211">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. VI. Comparison between liver and red blood cell phospholipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>33</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr11-0148607112439211">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. VII. Brain phospholipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>39</fpage>-<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr12-0148607112439211">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. VIII. Comparison between liver and brain phospholipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>46</fpage>-<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112439211">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. IX. Comparison between red blood cell and brain phospholipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>52</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112439211">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. X. Δ9-desaturase-catalyzed interconversion of fatty acids in extrahepatic sites</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>54</fpage>-<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112439211">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Larondelle</surname><given-names>Y</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. XI. Liver triglycerides</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>60</fpage>-<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112439211">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. XII. Adipose tissue lipids</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>67</fpage>-<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112439211">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Larondelle</surname><given-names>Y</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. XIII. Body weight and food intake</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>72</fpage>-<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112439211">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Louchami</surname><given-names>K</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. XIV. Plasma insulin and glucose, insulinogenic index and insulin resistance HOMA</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>78</fpage>-<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr19-0148607112439211">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Larondelle</surname><given-names>Y</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>The metabolic syndrome of ω-3-depleted rats: dietary changes in lipid fatty acid pattern without changes in total lipid content. XV. Comprehensive view</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2011</year>;<volume>4</volume>(<supplement>suppl 1</supplement>):<fpage>81</fpage>-<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr20-0148607112439211">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waitzberg</surname><given-names>DL</given-names></name>
<name><surname>Torrinhass</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Fish oil lipid emulsions and immune response: what clinicians need to know</article-title>. <source>Nutr Clin Pract</source>. <year>2009</year>;<volume>24</volume>:<fpage>487</fpage>-<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr21-0148607112439211">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laviano</surname><given-names>A</given-names></name>
<name><surname>Rossi Fanelli</surname><given-names>F</given-names></name>
</person-group>. <article-title>Lipid emulsions in parenteral nutrition: does one size fits all?</article-title> <source>S Afr J Clin Nutr</source>. <year>2010</year>;<volume>23</volume>:<fpage>S08</fpage>-<lpage>S10</lpage>.</citation>
</ref>
<ref id="bibr22-0148607112439211">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sabater</surname><given-names>J</given-names></name>
<name><surname>Masclans</surname><given-names>JR</given-names></name>
<name><surname>Sacanell</surname><given-names>J</given-names></name>
<name><surname>Chacon</surname><given-names>P</given-names></name>
<name><surname>Sabin</surname><given-names>P</given-names></name>
<name><surname>Planas</surname><given-names>M</given-names></name>
</person-group>. <article-title>Effect of an omega-3 fatty acid–enriched lipid emulsion on eicosanoid synthesis in acute respiratory distress syndrome (ARDS): a prospective, randomized, double-blind, parallel group study</article-title>. <source>Nutr Metab (London)</source>. <year>2011</year>;<volume>8</volume>:<fpage>22</fpage>-<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr23-0148607112439211">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jurewitsch</surname><given-names>B</given-names></name>
<name><surname>Gardiner</surname><given-names>G</given-names></name>
<name><surname>Naccarato</surname><given-names>M</given-names></name>
<name><surname>Jeejeebhoy</surname><given-names>KN</given-names></name>
</person-group>. <article-title>Omega 3–enriched lipid emulsion for liver salvage in parenteral nutrition–induced cholestasis in the adult patient</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>:<fpage>386</fpage>-<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr24-0148607112439211">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Dupont</surname><given-names>IE</given-names></name>
<name><surname>Deckelbaum</surname><given-names>RJ</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Rapid cellular enrichment of eicosapentaenoate after a single intravenous injection of a novel medium-chain triacylglycerol:fish oil emulsion in humans</article-title>. <source>Am J Clin Nutr</source>. <year>2010</year>;<volume>91</volume>:<fpage>875</fpage>-<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr25-0148607112439211">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
</person-group>. <article-title>Intravenous lipid emulsions to deliver omega 3 fatty acids</article-title>. <source>Prostag Leukotr Ess</source>. <year>2006</year>;<volume>75</volume>:<fpage>145</fpage>-<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr26-0148607112439211">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Dupont</surname><given-names>I</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Preclinical investigations of a medium-chain triglyceride:fish oil emulsion, I: effects of bovine milk lipoprotein lipase on lipid composition</article-title>. <source>Int J Mol Med</source>. <year>2006</year>;<volume>18</volume>:<fpage>761</fpage>-<lpage>773</lpage>.</citation>
</ref>
<ref id="bibr27-0148607112439211">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Preclinical investigations of a medium-chain triglyceride fish oil emulsion, II: lipoprotein lipase-catalyzed hydrolysis of long-chain polyunsaturated ω-3 fatty acids</article-title>. <source>Curr Top Biotechnol</source>. <year>2007</year>;<volume>3</volume>:<fpage>25</fpage>-<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr28-0148607112439211">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Dupont</surname><given-names>I</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Preclinical investigations of a medium-chain triglyceride:fish oil emulsion, III: experiments in cultured endothelial cells</article-title>. <source>Int J Mol Med</source>. <year>2006</year>;<volume>18</volume>:<fpage>1177</fpage>-<lpage>1185</lpage>.</citation>
</ref>
<ref id="bibr29-0148607112439211">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oguzhan</surname><given-names>B</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Louchami</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Pancreatic islet function in ω-3 fatty acid–depleted rats: glucose metabolism and nutrient-stimulated insulin release</article-title>. <source>Endocrine</source>. <year>2006</year>;<volume>29</volume>:<fpage>457</fpage>-<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr30-0148607112439211">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Louchami</surname><given-names>K</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Oguzhan</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Rapid changes in liver lipid composition and pancreatic K<sup>+</sup> handling and secretory behaviour provoked by the intravenous administration of a medium-chain triglyceride:fish oil emulsion to long-chain polyunsaturated ω-3 fatty acid–depleted rats</article-title>. <source>Int J Mol Med</source>. <year>2006</year>;<volume>18</volume>:<fpage>1047</fpage>-<lpage>1055</lpage>.</citation>
</ref>
<ref id="bibr31-0148607112439211">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Fontaine</surname><given-names>D</given-names></name>
<name><surname>Otto</surname><given-names>A</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Fontaine</surname><given-names>J</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Sustained enrichment of liver phospholipids and triglycerides in eicosapentaenoate after a bolus intravenous injection of a medium-chain triglycerides:fish oil emulsion to streptozotocin (type 1) and Goto-Kakizaki (type 2) diabetic rats</article-title>. <source>Int J Mol Med</source>. <year>2006</year>;<volume>17</volume>:<fpage>643</fpage>-<lpage>647</lpage>.</citation>
</ref>
<ref id="bibr32-0148607112439211">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oguzhan</surname><given-names>B</given-names></name>
<name><surname>Sancho</surname><given-names>V</given-names></name>
<name><surname>Acitores</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Alteration of adipocyte metabolism in ω-3 fatty acid–depleted rats</article-title>. <source>Horm Metab Res</source>. <year>2006</year>;<volume>38</volume>:<fpage>789</fpage>-<lpage>798</lpage>.</citation>
</ref>
<ref id="bibr33-0148607112439211">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Sebedio</surname><given-names>JL</given-names></name>
<name><surname>Leverve</surname><given-names>X</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Rapid reduction of liver steatosis in rats injected with a novel lipid emulsion</article-title>. <source>Horm Metab Res</source>. <year>2008</year>;<volume>40</volume>:<fpage>875</fpage>-<lpage>879</lpage>.</citation>
</ref>
<ref id="bibr34-0148607112439211">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Rapid lipid enrichment in ω-3 fatty acids: liver data</article-title>. <source>Int J Mol Med</source>. <year>2008</year>;<volume>21</volume>:<fpage>367</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr35-0148607112439211">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Preferential enrichment of liver phospholipids in docosahexaenoate relative to eicosapentaenoate in ω-3-depleted rats injected with a medium-chain triglyceride:fish oil emulsion</article-title>. <source>Prostag Leukotr Ess</source>. <year>2008</year>;<volume>78</volume>:<fpage>27</fpage>-<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr36-0148607112439211">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Delporte</surname><given-names>C</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Fatty acid pattern of epiploic and parametrial lipids in second generation rats depleted in long-chain polyunsaturated ω-3 fatty acids</article-title>. <source>Trends Cell Mol Biol</source>. <year>2007</year>;<volume>2</volume>:<fpage>55</fpage>-<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr37-0148607112439211">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agascioglu</surname><given-names>E</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Phospholipid fatty acid pattern and D-glucose metabolism in muscles from ω-3 fatty acid–depleted rats</article-title>. <source>Biochimie</source>. <year>2007</year>;<volume>89</volume>:<fpage>374</fpage>-<lpage>382</lpage>.</citation>
</ref>
<ref id="bibr38-0148607112439211">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Agascioglu</surname><given-names>E</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Rapid effects of the intravenous injection of a medium-chain triglyceride:fish oil emulsion on the triglyceride fatty acid pattern of soleus muscle from ω-3 fatty acid–depleted rats</article-title>. <source>Horm Metab Res</source>. <year>2007</year>;<volume>39</volume>:<fpage>202</fpage>-<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr39-0148607112439211">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Perturbation and age-related changes in the fatty acid pattern of soleus muscle phospholipids and triglycerides in rats depleted in long-chain polyunsaturated ω-3 fatty acids</article-title>. <source>Int J Mol Med</source>. <year>2007</year>;<volume>20</volume>:<fpage>897</fpage>-<lpage>904</lpage>.</citation>
</ref>
<ref id="bibr40-0148607112439211">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Brain phospholipid and triglyceride fatty acid content and pattern in rats depleted in long-chain polyunsaturated ω-3 fatty acids</article-title>. <source>Trends Cell Mol Biol</source>. <year>2007</year>;<volume>2</volume>:<fpage>69</fpage>-<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr41-0148607112439211">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Phospholipid and triglyceride fatty acid content and pattern in the heart of rats depleted in long-chain polyunsaturated ω-3 fatty acids</article-title>. <source>Nutr Res</source>. <year>2008</year>;<volume>28</volume>:<fpage>51</fpage>-<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr42-0148607112439211">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Louchami</surname><given-names>K</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Alteration of lipid fatty acid profile and cationic fluxes in ventricular cardiomyocytes from ω-3-depleted rats</article-title>. <source>Int J Mol Med</source>. <year>2009</year>;<volume>24</volume>:<fpage>343</fpage>-<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr43-0148607112439211">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delporte</surname><given-names>C</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Jurysta</surname><given-names>C</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Altered fatty acid pattern of phospholipids and triglycerides in the submandibular gland of ω-3-depleted rats</article-title> [erratum in: <italic>Eur J Oral Sci</italic>. 2007;115(4):338]. <source>Eur J Oral Sci</source>. <year>2007</year>;<volume>115</volume>:<fpage>103</fpage>-<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr44-0148607112439211">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Accelerated clearance of plasma triglycerides and free fatty acids in ω-3-depleted rats</article-title>. <source>Horm Metab Res</source>. <year>2007</year>;<volume>39</volume>:<fpage>295</fpage>-<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr45-0148607112439211">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Age-related perturbations of plasma lipid fatty acid content and pattern in ω-3-depleted rats examined before and shortly after the intravenous injection of two distinct lipid emulsions</article-title>. <source>Trends Cell Mol Biol</source>. <year>2007</year>;<volume>2</volume>:<fpage>35</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr46-0148607112439211">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Rapid lipid enrichment in ω-3 fatty acids: plasma data</article-title>. <source>Int J Mol Med</source>. <year>2008</year>;<volume>21</volume>:<fpage>355</fpage>-<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr47-0148607112439211">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Chardigny</surname><given-names>J-M</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Alteration of desaturase- and elongase-catalyzed steady-state equilibrium between selected fatty acids in liver phospholipids and triglycerides of ω-3-depleted rats: comparison with plasma lipids</article-title>. <source>Res Rev Biosci</source>. <year>2007</year>;<volume>1</volume>:<fpage>59</fpage>-<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr48-0148607112439211">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
</person-group>. <article-title>Phospholipid and triglyceride content in α-linolenic, eicosapentaenoic, docosapentaenoic and docosahexaenoic acid in the liver of normal and ω-3-fatty acid–depleted rats: comparison with corresponding plasma values</article-title>. <source>Res Rev Biosci</source>. <year>2007</year>;<volume>1</volume>:<fpage>69</fpage>-<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr49-0148607112439211">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Rapid lipid enrichment in ω-3 fatty acids: cause-to-effect relationships</article-title>. <source>Int J Mol Med</source>. <year>2008</year>;<volume>21</volume>:<fpage>375</fpage>-<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr50-0148607112439211">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Oguzhan</surname><given-names>B</given-names></name>
<name><surname>Louchami</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Pancreatic islet function in ω-3 fatty acid–depleted rats: alteration of calcium fluxes and calcium-dependent insulin release</article-title>. <source>Am J Physiol</source>. <year>2006</year>;<volume>291</volume>:<fpage>E441</fpage>-<lpage>E448</lpage>.</citation>
</ref>
<ref id="bibr51-0148607112439211">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Louchami</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Alteration of K<sup>+</sup> fluxes and insulin release in pancreatic islets from ω-3 fatty acid–depleted rats</article-title>. <source>Endocrine</source>. <year>2006</year>;<volume>30</volume>:<fpage>207</fpage>-<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr52-0148607112439211">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Courtois</surname><given-names>P</given-names></name>
<name><surname>Louchami</surname><given-names>K</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Effects of a medium-chain triglyceride:fish oil emulsion administered intravenously to ω-3 fatty acid–depleted rats on cationic fluxes in aortic rings</article-title>. <source>Int J Mol Med</source>. <year>2005</year>;<volume>16</volume>:<fpage>1089</fpage>-<lpage>1093</lpage>.</citation>
</ref>
<ref id="bibr53-0148607112439211">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fontaine</surname><given-names>D</given-names></name>
<name><surname>Otto</surname><given-names>A</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Protection of aortic endothelial function in both normal and diabetic rats by intravenous bolus injection of a medium-chain triglyceride:fish oil emulsion</article-title>. <source>Int J Mol Med</source>. <year>2006</year>;<volume>18</volume>:<fpage>697</fpage>-<lpage>704</lpage>.</citation>
</ref>
<ref id="bibr54-0148607112439211">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peltier</surname><given-names>S</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Acute in vivo administration of a fish oil–containing emulsion improves post-ischemic cardiac function in ω-3-depleted rats</article-title>. <source>Int J Mol Med</source>. <year>2006</year>;<volume>18</volume>:<fpage>741</fpage>-<lpage>749</lpage>.</citation>
</ref>
<ref id="bibr55-0148607112439211">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Louchami</surname><given-names>K</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Sener</surname><given-names>A</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Phospholipid and triacylglycerol fatty acid content and pattern in the cardiac endothelium of rats depleted in long-chain polyunsaturated ω-3 fatty acids</article-title>. <source>Cell Biochem Funct</source>. <year>2008</year>;<volume>26</volume>:<fpage>33</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr56-0148607112439211">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Hacquebard</surname><given-names>M</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Fatty acid pattern of platelet and white blood cell phospholipids after intravenous injection of a medium-chain triglyceride:fish oil emulsion in normal subjects</article-title>. <source>Metab Funct Res Diabetes</source>. <year>2010</year>;<volume>3</volume>:<fpage>1</fpage>-<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr57-0148607112439211">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pradier</surname><given-names>O</given-names></name>
<name><surname>Portois</surname><given-names>L</given-names></name>
<name><surname>Malaisse</surname><given-names>WJ</given-names></name>
<name><surname>Carpentier</surname><given-names>YA</given-names></name>
</person-group>. <article-title>Hemostatic safety of the bolus intravenous injection of a novel medium-chain triglyceride:fish oil emulsion</article-title>. <source>Int J Mol Med</source>. <year>2008</year>;<volume>22</volume>:<fpage>301</fpage>-<lpage>307</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>